ACHIEVE
Research type
Research Study
Full title
Aldosterone bloCkade for Health ImproVement Evaluation in End-stage renal disease (ACHIEVE)
IRAS ID
261542
Contact name
Patrick Mark
Contact email
Sponsor organisation
Hamilton Health Sciences
Eudract number
2020-003948-82
Clinicaltrials.gov Identifier
Duration of Study in the UK
4 years, 8 months, 0 days
Research summary
Patients with kidney failure requiring dialysis are at very high risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients requiring dialysis. Spironolactone is a pill used to treat and prevent heart failure in patients that do not require dialysis. It works by blocking a hormone (aldosterone) that causes high blood pressure and can damage the heart. Although spironolactone is very effective in patients that do not require dialysis, it is not known if spironolactone is effective in dialysis patients. Pilot studies suggest that spironolactone is safe in this patient group. This clinical trial will compare spironolactone to a dummy pill to determine if spironolactone reduces heart failure and heart related deaths in dialysis patients as well as checking if spironolactone is well tolerated in these patients. This is an internationals multi-centre study, which will run for approximately five years and study over 3000 patients, to produce a definitive answer is spironolactone reduces cardiovascular events in patients requiring dialysis.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
21/EE/0004
Date of REC Opinion
14 Jan 2021
REC opinion
Favourable Opinion